UAB Anti-Cancer Research Featured in Scientific AmericanAugust 25, 2008BIRMINGHAM, Ala. - Scientific American magazine focused on two University of Alabama at Birmingham (UAB) Comprehensive Cancer Center researchers in a news story on experimental next-generation anti-cancer therapies. David T. Curiel, M.D., Ph.D., is a UAB professor of medicine and director of the human gene therapy division, and Ronald Alvarez, M.D., is a UAB professor of medicine and director of the gynecologic oncology division. Both doctors are featured in a Scientific American special cancer edition, and both served as co-authors on the story "Tumor-busting viruses." The editors chose Curiel and Alvarez because of their research into a field call viral gene therapy, or virotherapy. Virotherapy involves an experimental technique to target viruses to cancer cells while leaving healthy cells untouched. The viruses are genetically engineered to kill tumor cells in different ways. One way is by adopting the viruses' natural ability to invade and reproduce as a way to deliver target genes that make tumor cells more susceptible to existing chemotherapies. Curiel and Alvarez have been testing this concept with a virus compound called adenovirus in women with recurrent ovarian or other gynecological cancers. The clinical trial is still in the early stages, yet the compound has shown anti-tumor effects that appear safe to most patients, Curiel said. "We envision a substantial role for viruses - that is, therapeutic viruses - in 21st-century medicine," Curiel and Alvarez wrote in wrote in the story. First proposed in the 1940s, virotherapy now relies heavily on adenoviruses, a cause of the common cold that has been studied and altered extensively for medical research. Adenoviruses have the ability to shuttle targeted segments of DNA into a tumor cell and make biochemical changes that minimize damage to healthy cells. University of Alabama at Birmingham |
|||||||||||||||||||||
| Related Anti-Cancer Current Events and Anti-Cancer News Articles CSHL study shows that some malignant tumors can be shut down after all Oncologists have had their hands tied because more than half of all human cancers have mutations that disable a protein called p53. New imagining technique could lead to better antibiotics and cancer drugs A recently devised method of imaging the chemical communication and warfare between microorganisms could lead to new antibiotics, antifungal, antiviral and anti-cancer drugs, said a Texas AgriLife Research scientist. Taking aim at mysterious DNA structures in the battle against cancer Designers of anti-cancer drugs are aiming their arrows at mysterious chunks of the genetic material DNA that may play a key role in preventing the growth and spread of cancer cells, according to an article in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine. A Potential Anti-cancer Agent Pateamine A (PatA), a natural product first isolated from marine sponges, has attracted considerable attention as a potential anti-cancer agent, and now a new activity has been found for it, which may reveal yet another anti-cancer mechanism. Duke develops nano-scale drug delivery for chemotherapy Going smaller could bring better results, especially when it comes to cancer-fighting drugs. Researchers use drug-radiation combo to eradicate lung cancer Researchers at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation. Next-generation microcapsules deliver 'chemicals on demand' Scientists in California are reporting development of a new generation of the microcapsules used in carbon-free copy paper, in which capsules burst and release ink with pressure from a pen. Sensor biochips could aid in cancer diagnosis and treatment It is very difficult to predict whether a cancer drug will help an individual patient: only around one third of drugs will work directly in a given patient. Bioluminescence imaging used for eye cancer detection At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery. KEAP1 Keeps major cancer-promoting protein at bay A tumor-suppressing protein snatches up an important cancer-promoting enzyme and tags it with molecules that condemn it to destruction, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports this week in the journal Molecular Cell. More Anti-Cancer Current Events and Anti-Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||